| 农 丽,陆永奎,唐芊芊,刘 燕,谭爱花,贾昱娴,覃芳卉.多柔比星脂质体在晚期乳腺癌治疗的疗效和安全性分析[J].,2024,(19):3781-3784 |
| 多柔比星脂质体在晚期乳腺癌治疗的疗效和安全性分析 |
| Efficacy and Safety Analysis of Pegylated Liposomal Doxorubicin in the Treatment of Advanced Breast Cancer |
| 投稿时间：2024-05-23 修订日期：2024-06-14 |
| DOI：10.13241/j.cnki.pmb.2024.19.048 |
| 中文关键词: 晚期乳腺癌 多柔比星脂质体 疗效 化疗 |
| 英文关键词: Advanced breast cancer Egylated liposomal doxorubicin (PLD) Efficacy Chemotherapy |
| 基金项目:广西壮族自治区卫生健康委员会计划课题（自筹经费科研Z-A20220687） |
|
| 摘要点击次数: 16 |
| 全文下载次数: 7 |
| 中文摘要: |
| 摘要 目的：探讨在既往使用过蒽环类药物的晚期乳腺癌患者中再使用多柔比星脂质体的临床疗效及毒副作用相关性分析。方法：回顾性分析2019年5月至2021年1月就诊于本院的79例使用含多柔比星脂质体方案治疗晚期乳腺癌患者的临床资料，并对晚期乳腺癌患者多柔比星脂质体再使用与初使用的临床疗效、影响因素及不良反应进行相关性分析。结果：79例患者中，有65例患者可以进行疗效评估，其中客观缓解率（ORR）为13.85%，疾病控制率（DCR）为63.08%，在HER-2阳性晚期乳腺癌中，抗Her-2 治疗联合多柔比星脂质体，ORR为20.00%，DCR为75.00%，中位无疾病进展生存时间（PFS）为3.23个月。最常见不良反应为骨髓抑制、手足综合征、口腔黏膜炎。结论：含多柔比星脂质体化疗辅助治疗晚期乳腺癌可获得较好疗效，抗HER-2治疗联合多柔比星脂质体对HER-2阳性晚期乳腺癌的疗效及安全性均较佳。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the clinical efficacy and the safety of pegylated liposomal doxorubicin (PLD) in patients with advanced breast cancer who had previously used anthracyclines. Methods: The clinical data of 79 patients with advanced breast cancer treated with PLD-contained regimen in our hospital from May 2019 to January 2021 were retrospectively analyzed. The clinical efficacy, influencing factors and adverse reactions were evaluated between the group of PDL re-use and initial use. Results: Among 79 patients, 65 patients could be evaluated for efficacy, of which the objective response rate (ORR) was 13.85%, and the disease control rate (DCR) was 63.08%. In HER-2 positive advanced breast cancer, the ORR was 20.00%, the DCR was 75.00%, and the median progression free survival (PFS) was 3.23 months. The most common adverse reactions are bone marrow suppression, hand foot syndrome, and oral mucositis. Conclusion: The adjuvant chemotherapy with doxorubicin liposomes can achieve good efficacy in the treatment of advanced breast cancer, and the anti HER-2 treatment combined with doxorubicin liposomes has better efficacy and safety in the treatment of HER-2 positive advanced breast cancer. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
